---

$0.77

-0.0138 ( +0.66% ) 1.5M

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-14	Sale	-19500.00	CHESS ROBERT
2024-05-20	Sale	-7355.00	Zalevsky Jonathan
2024-05-20	Sale	-16650.00	ROBIN HOWARD W
2024-05-20	Sale	-6260.00	Wilson Mark Andrew
2024-05-13	Sale	-56000.00	Deep Track Capital, LP
2024-02-22	Sale	-20033.00	ROBIN HOWARD W
2024-02-22	Sale	-9014.00	Zalevsky Jonathan
2024-02-22	Sale	-7606.00	Wilson Mark Andrew
2023-12-15	Sale	-325000.00	Wilson Mark Andrew
2023-12-15	Sale	-250000.00	Zalevsky Jonathan

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.